Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  WuXi AppTec Co., Ltd.    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
11/14/2019 11/15/2019 11/18/2019 11/19/2019 11/20/2019 Date
98.34(c) 97.13(c) 97.15(c) 98.8(c) 98.4 Last
11 276 515 6 492 852 5 309 899 8 587 137 10 101 767 Volume
+2.17% -1.23% +0.02% +1.70% -0.40% Change
More quotes
Financials (CNY)
Sales 2019 12 532 M
EBIT 2019 2 632 M
Net income 2019 2 317 M
Finance 2019 8 293 M
Yield 2019 0,44%
Sales 2020 15 948 M
EBIT 2020 3 360 M
Net income 2020 2 950 M
Finance 2020 8 583 M
Yield 2020 0,50%
P/E ratio 2019 69,3x
P/E ratio 2020 56,9x
EV / Sales2019 12,1x
EV / Sales2020 9,50x
Capitalization 160 B
More Financials
Company
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as... 
More about the company
Surperformance© ratings of WuXi AppTec Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on WUXI APPTEC CO., LTD.
11/18WUXI APPTEC : Lab Testing Division Expands Toxicology Facility in Suzhou, China
AQ
11/11WUXI APPTEC : Dr. Ge Li Awarded 'CEO of the Year' at CPhI Worldwide 2019
AQ
11/07WUXI APPTEC : Receives Investment Grade Corporate Ratings from Three Global Rati..
AQ
10/31WUXI APPTEC : Reports Third-Quarter 2019 Results
AQ
10/29WUXI APPTEC : Indicative announcement regarding the third h share class meeting
PU
10/28WUXI APPTEC : STA's Jinshan Facility Passes EMA Inspection
AQ
10/28WUXI APPTEC : Supplemental announcement in relation to the annual report for the..
PU
10/11WUXI APPTEC : Research Service Division and BioSolveIT Introduce GalaXi, a Vast ..
AQ
10/04WUXI APPTEC : Form of proxy for the third h share class meeting for 2019 to be h..
PU
10/04WUXI APPTEC : Reply slip for the third h share class meeting for 2019 to be held..
PU
10/04WUXI APPTEC : Notice of the third h share class meeting for 2019
PU
10/04WUXI APPTEC : (1) proposed adoption of the list of incentive participants; and (..
PU
09/22WUXI APPTEC CO., LTD. : Proxy Statments
CO
08/20WUXI APPTEC : Reports First Half 2019 Interim Results
AQ
08/19WUXI APPTEC CO., LTD. : Half-year results
CO
More news
News in other languages on WUXI APPTEC CO., LTD.
2018Hong Kong parti pour être en tête du classement des IPO en 2018
2018Fosun Tourism (Club Med) lève 428 millions de dollars lors de son IPO à Hong ..
More news
Sector news : Bio Therapeutic Drugs
11/19Akcea, Ionis Close Licensing Agreement with Pfizer on New Drug
DJ
11/19GENMAB : EC Approves Expanded Darzalex Use in Multiple Myeloma
DJ
11/18A lot happening on the M&A side
11/18Qiagen shares surge as diagnostics group says open to takeover talks
RE
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
More sector news : Bio Therapeutic Drugs
Chart WUXI APPTEC CO., LTD.
Duration : Period :
WuXi AppTec Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI APPTEC CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 97,37  CNY
Last Close Price 98,80  CNY
Spread / Highest target 8,98%
Spread / Average Target -1,45%
Spread / Lowest Target -13,2%
EPS Revisions
Managers
NameTitle
Edward Hu Co-Chief Executive Officer, CIO & Director
Ge Li Chairman, President & Co-Chief Executive Officer
Harry He Chairman-Supervisory Board
Ellis Chu Chief Financial Officer
Frederick H. Hausheer Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.84.77%22 783
GILEAD SCIENCES3.92%81 336
VERTEX PHARMACEUTICALS29.74%54 001
REGENERON PHARMACEUTICALS-7.78%37 191
GENMAB41.12%14 773
BEIGENE, LTD.45.37%11 883